AUG 12, 2026 · PHASE 3 TRIAL
An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Everolimus in First to Third Line LAR Subtype TNBC
ClinicalTrials.gov
This is a clinical trial registry record for a planned Phase 3 study with no results posted; recruitment has not yet begun.
Reported
PhasePHASE 3
Planned enrollment180
Primary outcome measureProgression Free Survival (PFS) at 24 months